Selected research
Industry Research
Mycoplasma Testing in Clinical Industry Research Report 2026
Market perspective
The global Mycoplasma Testing in Clinical market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Mycoplasma Testing in Clinical market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Mycoplasma Testing in Clinical market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Mycoplasma Testing in Clinical market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Mycoplasma Testing in Clinical include Charles River Laboratories International, Thermo Fisher Scientific, SGS, Bionique Testing Laboratories, WuXi AppTec, Labcorp, IDEXX BioAnalytics, WiCell and Creative Biogene, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Mycoplasma Testing in Clinical market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Mycoplasma Testing in Clinical.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mycoplasma Testing in Clinical Market by Company
Charles River Laboratories International
Thermo Fisher Scientific
SGS
Bionique Testing Laboratories
WuXi AppTec
Labcorp
IDEXX BioAnalytics
WiCell
Creative Biogene
Eurofins Scientific
Hylabs
JOINN Laboratories
Shimadzu Diagnostics
CellSafe
FullHope Biomedical
Syngene International
Beyotime
CTI Cert
Shenke Bio
Mycoplasma Testing in Clinical Segment by Type
Culture-based Mycoplasma Detection
PCR/qPCR Mycoplasma Detection
Others
Mycoplasma Testing in Clinical Segment by Application
Hospitals
Clinical Laboratories
Public Health Institutions
Third-Party Medical Testing Centers
Others
Mycoplasma Testing in Clinical Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mycoplasma Testing in Clinical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mycoplasma Testing in Clinical and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mycoplasma Testing in Clinical.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Mycoplasma Testing in Clinical companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Culture-based Mycoplasma Detection
- PCR/qPCR Mycoplasma Detection
- Others
Applications
- Hospitals
- Clinical Laboratories
- Public Health Institutions
- Third-Party Medical Testing Centers
- Others
Companies covered
- Charles River Laboratories International
- Thermo Fisher Scientific
- SGS
- Bionique Testing Laboratories
- WuXi AppTec
- Labcorp
- IDEXX BioAnalytics
- WiCell
- Creative Biogene
- Eurofins Scientific
- Hylabs
- JOINN Laboratories
- Shimadzu Diagnostics
- CellSafe
- FullHope Biomedical
- Syngene International
- Beyotime
- CTI Cert
- Shenke Bio
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Mycoplasma Testing in Clinical by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Culture-based Mycoplasma Detection
- 2.2.3 PCR/qPCR Mycoplasma Detection
- 2.2.4 Others
- 2.3 Mycoplasma Testing in Clinical by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Clinical Laboratories
- 2.3.4 Public Health Institutions
- 2.3.5 Third-Party Medical Testing Centers
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Mycoplasma Testing in Clinical Breakdown Data by Type
- 3.1 Global Mycoplasma Testing in Clinical Historic Market Size by Type (2021-2026)
- 3.2 Global Mycoplasma Testing in Clinical Forecasted Market Size by Type (2027-2032)
4 Mycoplasma Testing in Clinical Breakdown Data by Application
- 4.1 Global Mycoplasma Testing in Clinical Historic Market Size by Application (2021-2026)
- 4.2 Global Mycoplasma Testing in Clinical Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Mycoplasma Testing in Clinical Market Perspective (2021-2032)
- 5.2 Global Mycoplasma Testing in Clinical Growth Trends by Region
- 5.2.1 Global Mycoplasma Testing in Clinical Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Mycoplasma Testing in Clinical Historic Market Size by Region (2021-2026)
- 5.2.3 Mycoplasma Testing in Clinical Forecasted Market Size by Region (2027-2032)
- 5.3 Mycoplasma Testing in Clinical Market Dynamics
- 5.3.1 Mycoplasma Testing in Clinical Industry Trends
- 5.3.2 Mycoplasma Testing in Clinical Market Drivers
- 5.3.3 Mycoplasma Testing in Clinical Market Challenges
- 5.3.4 Mycoplasma Testing in Clinical Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Mycoplasma Testing in Clinical Players by Revenue
- 6.1.1 Global Top Mycoplasma Testing in Clinical Players by Revenue (2021-2026)
- 6.1.2 Global Mycoplasma Testing in Clinical Revenue Market Share by Players (2021-2026)
- 6.2 Global Mycoplasma Testing in Clinical Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Mycoplasma Testing in Clinical Head Office and Area Served
- 6.4 Global Mycoplasma Testing in Clinical Players, Product Type & Application
- 6.5 Global Mycoplasma Testing in Clinical Manufacturers Established Date
- 6.6 Global Mycoplasma Testing in Clinical Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Mycoplasma Testing in Clinical Market Size (2021-2032)
- 7.2 North America Mycoplasma Testing in Clinical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Mycoplasma Testing in Clinical Market Size by Country (2021-2026)
- 7.4 North America Mycoplasma Testing in Clinical Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Mycoplasma Testing in Clinical Market Size (2021-2032)
- 8.2 Europe Mycoplasma Testing in Clinical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Mycoplasma Testing in Clinical Market Size by Country (2021-2026)
- 8.4 Europe Mycoplasma Testing in Clinical Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Mycoplasma Testing in Clinical Market Size (2021-2032)
- 9.2 Asia-Pacific Mycoplasma Testing in Clinical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Mycoplasma Testing in Clinical Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Mycoplasma Testing in Clinical Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Mycoplasma Testing in Clinical Market Size (2021-2032)
- 10.2 South America Mycoplasma Testing in Clinical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Mycoplasma Testing in Clinical Market Size by Country (2021-2026)
- 10.4 South America Mycoplasma Testing in Clinical Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Mycoplasma Testing in Clinical Market Size (2021-2032)
- 11.2 Middle East & Africa Mycoplasma Testing in Clinical Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Mycoplasma Testing in Clinical Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Mycoplasma Testing in Clinical Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Charles River Laboratories International
- 12.1.1 Charles River Laboratories International Company Information
- 12.1.2 Charles River Laboratories International Business Overview
- 12.1.3 Charles River Laboratories International Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.1.4 Charles River Laboratories International Mycoplasma Testing in Clinical Product Portfolio
- 12.1.5 Charles River Laboratories International Recent Developments
- 12.2 Thermo Fisher Scientific
- 12.2.1 Thermo Fisher Scientific Company Information
- 12.2.2 Thermo Fisher Scientific Business Overview
- 12.2.3 Thermo Fisher Scientific Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.2.4 Thermo Fisher Scientific Mycoplasma Testing in Clinical Product Portfolio
- 12.2.5 Thermo Fisher Scientific Recent Developments
- 12.3 SGS
- 12.3.1 SGS Company Information
- 12.3.2 SGS Business Overview
- 12.3.3 SGS Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.3.4 SGS Mycoplasma Testing in Clinical Product Portfolio
- 12.3.5 SGS Recent Developments
- 12.4 Bionique Testing Laboratories
- 12.4.1 Bionique Testing Laboratories Company Information
- 12.4.2 Bionique Testing Laboratories Business Overview
- 12.4.3 Bionique Testing Laboratories Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.4.4 Bionique Testing Laboratories Mycoplasma Testing in Clinical Product Portfolio
- 12.4.5 Bionique Testing Laboratories Recent Developments
- 12.5 WuXi AppTec
- 12.5.1 WuXi AppTec Company Information
- 12.5.2 WuXi AppTec Business Overview
- 12.5.3 WuXi AppTec Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.5.4 WuXi AppTec Mycoplasma Testing in Clinical Product Portfolio
- 12.5.5 WuXi AppTec Recent Developments
- 12.6 Labcorp
- 12.6.1 Labcorp Company Information
- 12.6.2 Labcorp Business Overview
- 12.6.3 Labcorp Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.6.4 Labcorp Mycoplasma Testing in Clinical Product Portfolio
- 12.6.5 Labcorp Recent Developments
- 12.7 IDEXX BioAnalytics
- 12.7.1 IDEXX BioAnalytics Company Information
- 12.7.2 IDEXX BioAnalytics Business Overview
- 12.7.3 IDEXX BioAnalytics Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.7.4 IDEXX BioAnalytics Mycoplasma Testing in Clinical Product Portfolio
- 12.7.5 IDEXX BioAnalytics Recent Developments
- 12.8 WiCell
- 12.8.1 WiCell Company Information
- 12.8.2 WiCell Business Overview
- 12.8.3 WiCell Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.8.4 WiCell Mycoplasma Testing in Clinical Product Portfolio
- 12.8.5 WiCell Recent Developments
- 12.9 Creative Biogene
- 12.9.1 Creative Biogene Company Information
- 12.9.2 Creative Biogene Business Overview
- 12.9.3 Creative Biogene Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.9.4 Creative Biogene Mycoplasma Testing in Clinical Product Portfolio
- 12.9.5 Creative Biogene Recent Developments
- 12.10 Eurofins Scientific
- 12.10.1 Eurofins Scientific Company Information
- 12.10.2 Eurofins Scientific Business Overview
- 12.10.3 Eurofins Scientific Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.10.4 Eurofins Scientific Mycoplasma Testing in Clinical Product Portfolio
- 12.10.5 Eurofins Scientific Recent Developments
- 12.11 Hylabs
- 12.11.1 Hylabs Company Information
- 12.11.2 Hylabs Business Overview
- 12.11.3 Hylabs Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.11.4 Hylabs Mycoplasma Testing in Clinical Product Portfolio
- 12.11.5 Hylabs Recent Developments
- 12.12 JOINN Laboratories
- 12.12.1 JOINN Laboratories Company Information
- 12.12.2 JOINN Laboratories Business Overview
- 12.12.3 JOINN Laboratories Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.12.4 JOINN Laboratories Mycoplasma Testing in Clinical Product Portfolio
- 12.12.5 JOINN Laboratories Recent Developments
- 12.13 Shimadzu Diagnostics
- 12.13.1 Shimadzu Diagnostics Company Information
- 12.13.2 Shimadzu Diagnostics Business Overview
- 12.13.3 Shimadzu Diagnostics Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.13.4 Shimadzu Diagnostics Mycoplasma Testing in Clinical Product Portfolio
- 12.13.5 Shimadzu Diagnostics Recent Developments
- 12.14 CellSafe
- 12.14.1 CellSafe Company Information
- 12.14.2 CellSafe Business Overview
- 12.14.3 CellSafe Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.14.4 CellSafe Mycoplasma Testing in Clinical Product Portfolio
- 12.14.5 CellSafe Recent Developments
- 12.15 FullHope Biomedical
- 12.15.1 FullHope Biomedical Company Information
- 12.15.2 FullHope Biomedical Business Overview
- 12.15.3 FullHope Biomedical Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.15.4 FullHope Biomedical Mycoplasma Testing in Clinical Product Portfolio
- 12.15.5 FullHope Biomedical Recent Developments
- 12.16 Syngene International
- 12.16.1 Syngene International Company Information
- 12.16.2 Syngene International Business Overview
- 12.16.3 Syngene International Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.16.4 Syngene International Mycoplasma Testing in Clinical Product Portfolio
- 12.16.5 Syngene International Recent Developments
- 12.17 Beyotime
- 12.17.1 Beyotime Company Information
- 12.17.2 Beyotime Business Overview
- 12.17.3 Beyotime Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.17.4 Beyotime Mycoplasma Testing in Clinical Product Portfolio
- 12.17.5 Beyotime Recent Developments
- 12.18 CTI Cert
- 12.18.1 CTI Cert Company Information
- 12.18.2 CTI Cert Business Overview
- 12.18.3 CTI Cert Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.18.4 CTI Cert Mycoplasma Testing in Clinical Product Portfolio
- 12.18.5 CTI Cert Recent Developments
- 12.19 Shenke Bio
- 12.19.1 Shenke Bio Company Information
- 12.19.2 Shenke Bio Business Overview
- 12.19.3 Shenke Bio Revenue in Mycoplasma Testing in Clinical Business (2021-2026)
- 12.19.4 Shenke Bio Mycoplasma Testing in Clinical Product Portfolio
- 12.19.5 Shenke Bio Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst